BioSpace News Archive

Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled “Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer,” based on work performed at the Crown Princess Mary Cancer Centre (“CPMCC”) at the University of Sydney, in Sydney, Australia.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 137,700 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®).

Encompass Health Corporation, the largest owner and operator of inpatient rehabilitation hospitals in the United States, reported its results of operations for the second quarter ended June 30, 2022 and affirmed its 2022 guidance.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 10,800 shares of G1’s common stock and 7,200 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on August 1, 2022, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 290,500 shares of its common stock to Andrea Paul.

TCR 2 Therapeutics Inc. today announced the Compensation Committee of the Board of Directors of TCR 2 approved the grant of inducement stock options covering an aggregate of 46,600 shares of TCR 2 ’s common stock to 2 new non-executive employees.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate KB407 in a clinical trial for cystic fibrosis.

Telix Pharmaceuticals Limited reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited.